Advertisement

The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment

  • Louise C. Connell
  • José Mauricio Mota
  • Maria Ignez BraghiroliEmail author
  • Paulo M. Hoff
Lower Gastrointestinal Cancers (AB Benson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lower Gastrointestinal Cancers

Opinion statement

Colorectal cancer (CRC) is the third leading cancer diagnosed globally and an important cause of cancer-related mortality. Of interest, while we have witnessed a declining incidence trend over the past few decades in the older population, incidence rates for adolescents and young adults have been increasing steadily. Several factors may well explain this apparent epidemic in the young, namely a lack of routine screening and emerging lifestyle issues such as obesity, lack of exercise, and dietary factors. It is known that both environmental and genetic factors can increase the likelihood of developing CRC. Although inherited susceptibility is associated with the most striking increases in risk, and must always be considered in a young patient with CRC, the majority of CRCs are in fact sporadic rather than familial. Early-onset CRC is a truly heterogeneous disease, with mounting evidence to suggest that this patient population has a distinctive molecular profile, very different to late-onset CRC cases. Currently, both younger and older patients with CRC are treated in essentially the same manner, but with a better understanding of the molecular mechanisms underlying CRC in the young, we will have the opportunity to specifically tailor screening and clinical management strategies in this unique patient population in an effort to improve outcomes. The aim of this review is to outline our current knowledge of the distinguishing features of early-onset CRC, the ongoing research efforts, and the evolving evidence in this field.

Keywords

Early-onset colorectal cancer Epidemiology Screening Hereditary syndromes Lynch syndrome Nonhereditary risk factors Sporadic early-onset colorectal cancer Chromosomal instability Microsatellite instability CpG island methylator phenotype 

Notes

Compliance with Ethical Standards

Conflict of Interest

Louise C. Connell, José Mauricio Mota, Maria Ignez Braghiroli, and Paulo M. Hoff declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107.PubMedCrossRefGoogle Scholar
  2. 2.
    Perea J, Rodríguez Y, Rueda D, Marín JC, Díaz-Tasende J, Álvaro E, et al. Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome. Ann Surg Oncol. 2011;18:3285–91. doi: 10.1245/s10434-011-1782-4.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang M-J, Ping J, Li Y, Adell G, Arbman G, Nodin B, et al. The prognostic factors and multiple biomarkers in young patients with colorectal cancer. Sci Rep. 2015;5:10645. doi: 10.1038/srep10645.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Kneuertz PJ, Chang GJ, Hu C-Y, Rodriguez-Bigas MA, Eng C, Vilar E, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015;150:402–9. doi: 10.1001/jamasurg.2014.3572.PubMedCrossRefGoogle Scholar
  5. 5.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi: 10.1002/ijc.29210.PubMedCrossRefGoogle Scholar
  6. 6.
    Howlader N, Noone A, Krapcho M, Miller D, K Bishop, SF Altekruse, et al. SEER cancer statistics review, 1975–2013. In: SEER web site [Internet]. 2016. Available: http://seer.cancer.gov/csr/1975_2013/.
  7. 7.
    Singh KE, Taylor TH, Pan C-JG, Stamos MJ, Zell JA. Colorectal cancer incidence among young adults in California. J Adolesc Young Adult Oncol. 2014;3:176–84. doi: 10.1089/jayao.2014.0006.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Young JP, Win AK, Rosty C, Flight I, Roder D, Young GP, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol. 2015;30:6–13. doi: 10.1111/jgh.12792.PubMedCrossRefGoogle Scholar
  9. 9.
    • Bailey CE, Hu C-Y, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17–22. doi: 10.1001/jamasurg.2014.1756. This retrospective cohort study based on the SEER CRC registry confirms the apparent increase in the incidence of CRC in young adults and a decline in older patientsPubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Investig Med. 2016; doi: 10.1136/jim-2016-000229.PubMedGoogle Scholar
  11. 11.
    Meyer JE, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer. 2010;116:4354–9. doi: 10.1002/cncr.25432.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Austin H, Henley SJ, King J, Richardson LC, Eheman C. Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening. Cancer Causes Control. 2014;25:191–201. doi: 10.1007/s10552-013-0321-y.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–72. Available: http://www.ncbi.nlm.nih.gov/pubmed/14570365 PubMedGoogle Scholar
  14. 14.
    Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomark Prev. 2009;18:1695–8. doi: 10.1158/1055-9965.EPI-09-0186.CrossRefGoogle Scholar
  15. 15.
    You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med. 2012;172:287–9. doi: 10.1001/archinternmed.2011.602.PubMedCrossRefGoogle Scholar
  16. 16.
    Griffin PM, Liff JM, Greenberg RS, Clark WS. Adenocarcinomas of the colon and rectum in persons under 40 years old. A population-based study. Gastroenterology. 1991;100:1033–40. Available: http://www.ncbi.nlm.nih.gov/pubmed/2001800 PubMedCrossRefGoogle Scholar
  17. 17.
    Rahman R, Schmaltz C, Jackson CS, Simoes EJ, Jackson-Thompson J, Ibdah JA. Increased risk for colorectal cancer under age 50 in racial and ethnic minorities living in the United States. Cancer Med. 2015;4:1863–70. doi: 10.1002/cam4.560.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Ashktorab H, Vilmenay K, Brim H, Laiyemo AO, Kibreab A, Nouraie M. Colorectal cancer in young African Americans: is it time to revisit guidelines and prevention? Dig Dis Sci. 2016;61:3026–30. doi: 10.1007/s10620-016-4207-1.PubMedCrossRefGoogle Scholar
  19. 19.
    • Holowatyj AN, Ruterbusch JJ, Rozek LS, Cote ML, Stoffel EM. Racial/ethnic disparities in survival among patients with young-onset colorectal cancer. J Clin Oncol. 2016;34:2148–56. doi: 10.1200/JCO.2015.65.0994. Using the SEER database, the survival of patients with young-onset CRC (aged <50 years) was assessed. It was observed that the survival for CRC diagnosed at a young age is significantly worse among non-Hispanic Black patients compared to non-Hispanic White patients, even in the setting of early-stage diseasePubMedCrossRefGoogle Scholar
  20. 20.
    Dozois EJ, Boardman LA, Suwanthanma W, Limburg PJ, Cima RR, Bakken JL, et al. Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome? Medicine (Baltimore). 2008;87:259–63. doi: 10.1097/MD.0b013e3181881354.CrossRefGoogle Scholar
  21. 21.
    O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28:558–62. Available: http://www.ncbi.nlm.nih.gov/pubmed/15366745 PubMedCrossRefGoogle Scholar
  22. 22.
    Taggarshe D, Rehil N, Sharma S, Flynn JC, Damadi A. Colorectal cancer: are the “young” being overlooked? Am J Surg. 2013;205:312–6. discussion 316 doi: 10.1016/j.amjsurg.2012.10.016.PubMedCrossRefGoogle Scholar
  23. 23.
    Teng A, Lee DY, Cai J, Patel SS, Bilchik AJ, Goldfarb MR. Patterns and outcomes of colorectal cancer in adolescents and young adults. J Surg Res. 2016;205:19–27. doi: 10.1016/j.jss.2016.05.036.PubMedCrossRefGoogle Scholar
  24. 24.
    Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer. 2016;122:929–34. doi: 10.1002/cncr.29716.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms or time to diagnosis. Clin Gastroenterol Hepatol. 2016; doi: 10.1016/j.cgh.2016.10.038.Google Scholar
  26. 26.
    Lisa A, Boardman EB. Genetics of young onset colorectal cancer. J Bone Marrow Res. 2014;3 doi: 10.4172/2161-1041.1000124.
  27. 27.
    Aarnio M. Clinicopathological features and management of cancers in Lynch syndrome. Patholog Res Int. 2012;2012:350309. doi: 10.1155/2012/350309.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Peltomäki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21:1174–9. doi: 10.1200/JCO.2003.04.060.PubMedCrossRefGoogle Scholar
  29. 29.
    Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137:1621–7. doi: 10.1053/j.gastro.2009.07.039.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32. doi: 10.1056/NEJMra012242.PubMedCrossRefGoogle Scholar
  31. 31.
    Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S, Shashidharan M, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer. 1998;83:259–66. Available: http://www.ncbi.nlm.nih.gov/pubmed/9669808 PubMedCrossRefGoogle Scholar
  32. 32.
    Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135:419–28. doi: 10.1053/j.gastro.2008.04.026.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10. doi: 10.1001/jama.2011.743.PubMedCrossRefGoogle Scholar
  34. 34.
    Wennstrom J, Pierce ER, McKusick VA. Hereditary benign and malignant lesions of the large bowel. Cancer. 1974;34:850–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/4604530 CrossRefGoogle Scholar
  35. 35.
    Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011;17:405–15. doi: 10.1097/PPO.0b013e318237e408.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101:385–98. doi: 10.1111/j.1572-0241.2006.00375.x.PubMedCrossRefGoogle Scholar
  37. 37.
    Cruz-Correa M, Giardiello FM. Familial adenomatous polyposis. Gastrointest Endosc. 2003;58:885–94. Available: http://www.ncbi.nlm.nih.gov/pubmed/14652558 PubMedCrossRefGoogle Scholar
  38. 38.
    Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep. 2012;14:428–38. doi: 10.1007/s11894-012-0280-6.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044–58. doi: 10.1053/j.gastro.2010.01.054.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22. doi: 10.1186/1750-1172-4-22.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol. 2009;27:3975–80. doi: 10.1200/JCO.2008.21.6853.PubMedCrossRefGoogle Scholar
  42. 42.
    Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet (London, England). 2003;362:39–41. doi: 10.1016/S0140-6736(03)13805-6.CrossRefGoogle Scholar
  43. 43.
    Jenkins MA, Croitoru ME, Monga N, Cleary SP, Cotterchio M, Hopper JL, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomark Prev. 2006;15:312–4. doi: 10.1158/1055-9965.EPI-05-0793.CrossRefGoogle Scholar
  44. 44.
    van Lier MGF, Wagner A, Mathus-Vliegen EMH, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz–Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105:1258–64. doi: 10.1038/ajg.2009.725.PubMedCrossRefGoogle Scholar
  45. 45.
    Jass JR, Williams CB, Bussey HJ, Morson BC. Juvenile polyposis—a precancerous condition. Histopathology. 1988;13:619–30. Available: http://www.ncbi.nlm.nih.gov/pubmed/2853131 PubMedCrossRefGoogle Scholar
  46. 46.
    Lachlan KL. Cowden syndrome and the PTEN hamartoma tumor syndrome: how to define rare genetic syndromes. J Natl Cancer Inst. 2013;105:1595–7. doi: 10.1093/jnci/djt290.PubMedCrossRefGoogle Scholar
  47. 47.
    Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol. 2012;107:770–8. doi: 10.1038/ajg.2012.52.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/12365955 PubMedCrossRefGoogle Scholar
  49. 49.
    Centers for Disease Control and Prevention (CDC). Trends in leisure-time physical inactivity by age, sex, and race/ethnicity—United States, 1994-2004. MMWR Morb Mortal Wkly Rep. 2005;54:991–4. Available: http://www.ncbi.nlm.nih.gov/pubmed/16208312 Google Scholar
  50. 50.
    Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol Biol. 2009;472:191–215. doi: 10.1007/978-1-60327-492-0_8.PubMedCrossRefGoogle Scholar
  51. 51.
    Slattery ML, Sorenson AW, Mahoney AW, French TK, Kritchevsky D, Street JC. Diet and colon cancer: assessment of risk by fiber type and food source. JNCI J Natl Cancer Inst. 1988;80:1474–80. doi: 10.1093/jnci/80.18.1474.PubMedCrossRefGoogle Scholar
  52. 52.
    Crosara Teixeira M, Braghiroli MI, Sabbaga J, Hoff PM. Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol. 2014;20:15060–9. doi: 10.3748/wjg.v20.i41.15060.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Lin J. Dietary fat and fatty acids and risk of colorectal cancer in women. Am J Epidemiol. 2004;160:1011–22. doi: 10.1093/aje/kwh319.PubMedCrossRefGoogle Scholar
  54. 54.
    Karahalios A, English DR, Simpson JA. Weight change and risk of colorectal cancer: a systematic review and meta-analysis. Am J Epidemiol. 2015;181:832–45. doi: 10.1093/aje/kwu357.PubMedCrossRefGoogle Scholar
  55. 55.
    Wolin KY, Yan Y, Colditz GA, Lee I-M. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009;100:611–6. doi: 10.1038/sj.bjc.6604917.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106:1911–21. doi: 10.1038/ajg.2011.301.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. JAMA. 2008;300:2765–78. doi: 10.1001/jama.2008.839.PubMedCrossRefGoogle Scholar
  58. 58.
    Wallace K, Grau MV, Ahnen D, Snover DC, Robertson DJ, Mahnke D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomark Prev. 2009;18:2310–7. doi: 10.1158/1055-9965.EPI-09-0211.CrossRefGoogle Scholar
  59. 59.
    Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology. 2008;134:388–95. doi: 10.1053/j.gastro.2007.11.007.PubMedCrossRefGoogle Scholar
  60. 60.
    Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol Off J Eur Soc Med Oncol. 2011;22:1958–72. doi: 10.1093/annonc/mdq653.CrossRefGoogle Scholar
  61. 61.
    Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med. 2004;140:603–13. Available: http://www.ncbi.nlm.nih.gov/pubmed/15096331 PubMedCrossRefGoogle Scholar
  62. 62.
    Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol. 2008;167:1397–406. doi: 10.1093/aje/kwn073.PubMedCrossRefGoogle Scholar
  63. 63.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi: 10.3322/caac.20073.PubMedCrossRefGoogle Scholar
  64. 64.
    Lynch KL, Ahnen DJ, Byers T, Weiss DG, Lieberman DA. First-degree relatives of patients with advanced colorectal adenomas have an increased prevalence of colorectal cancer. Clin Gastroenterol Hepatol. 2003;1:96–102. doi: 10.1053/cgh.2003.50018.PubMedCrossRefGoogle Scholar
  65. 65.
    Lieberman DA, Prindiville S, Weiss DG, Willett W, VA Cooperative Study Group 380. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290:2959–67. doi: 10.1001/jama.290.22.2959.PubMedCrossRefGoogle Scholar
  66. 66.
    Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331:1669–74. doi: 10.1056/NEJM199412223312501.PubMedCrossRefGoogle Scholar
  67. 67.
    Butterworth AS, Higgins JPT, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006;42:216–27. doi: 10.1016/j.ejca.2005.09.023.PubMedCrossRefGoogle Scholar
  68. 68.
    Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–57. doi: 10.1053/j.gastro.2012.06.001.PubMedCrossRefGoogle Scholar
  69. 69.
    Qaseem A, Denberg TD, Hopkins RH, Humphrey LL, Levine J, Sweet DE, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012;156:378–86. doi: 10.7326/0003-4819-156-5-201203060-00010.PubMedCrossRefGoogle Scholar
  70. 70.
    Gupta AK, Samadder J, Elliott E, Sethi S, Schoenfeld P. Prevalence of any size adenomas and advanced adenomas in 40- to 49-year-old individuals undergoing screening colonoscopy because of a family history of colorectal carcinoma in a first-degree relative. Gastrointest Endosc. 2011;74:110–8. doi: 10.1016/j.gie.2011.02.010.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Garcia GH, Riechelmann RP, Hoff PM. Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer. Clinics (Sao Paulo). 2015;70:696–9. doi: 10.6061/clinics/2015(10)07.CrossRefGoogle Scholar
  72. 72.
    Akhtar S, Sinha S, McKenzie S, Sagar PM, Finan PJ, Burke D. Awareness of risk factors amongst first degree relative patients with colorectal cancer. Color Dis. 2008;10:887–90. doi: 10.1111/j.1463-1318.2008.01502.x.Google Scholar
  73. 73.
    Hogan NM, Hanley M, Hogan AM, Sheehan M, McAnena OJ, Regan MP, et al. Awareness and uptake of family screening in patients diagnosed with colorectal cancer at a young age. Gastroenterol Res Pract. 2015;2015:194931. doi: 10.1155/2015/194931.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Austin GL, Goldstein JI, Peters SL, Ahnen DJ. Are colorectal cancer screening recommendations for first-degree relatives of patients with adenomas too aggressive? Clin Gastroenterol Hepatol. 2011;9:308–13. doi: 10.1016/j.cgh.2011.01.004.PubMedCrossRefGoogle Scholar
  75. 75.
    Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum. 2014;57:1025–48. doi: 10.1097/DCR.000000000000000.PubMedCrossRefGoogle Scholar
  76. 76.
    Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MWY, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015;33:209–17. doi: 10.1200/JCO.2014.58.1322.PubMedCrossRefGoogle Scholar
  77. 77.
    Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guidelines Working Group. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(Suppl 6):vi73–80. doi: 10.1093/annonc/mdt209.Google Scholar
  78. 78.
    Barrow P, Khan M, Lalloo F, Evans DG, Hill J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg. 2013;100:1719–31. doi: 10.1002/bjs.9316.CrossRefPubMedGoogle Scholar
  79. 79.
    Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34. Available: http://www.ncbi.nlm.nih.gov/pubmed/10784581 PubMedCrossRefGoogle Scholar
  80. 80.
    Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med. 1998;129:787–96. Available: http://www.ncbi.nlm.nih.gov/pubmed/9841584 PubMedCrossRefGoogle Scholar
  81. 81.
    Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2014;147:502–26. doi: 10.1053/j.gastro.2014.04.001.PubMedCrossRefGoogle Scholar
  82. 82.
    Vasen HFA, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57:704–13. doi: 10.1136/gut.2007.136127.PubMedCrossRefGoogle Scholar
  83. 83.
    Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62. quiz 263 doi: 10.1038/ajg.2014.435.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Provenzale D, Gupta S, Ahnen DJ, Bray T, Cannon JA, Cooper G, et al. Genetic/familial high-risk assessment: colorectal version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:1010–30. Available: http://www.ncbi.nlm.nih.gov/pubmed/27496117 CrossRefGoogle Scholar
  85. 85.
    Sengupta N, Yee E, Feuerstein JD. Colorectal cancer screening in inflammatory bowel disease. Dig Dis Sci. 2016;61:980–9. doi: 10.1007/s10620-015-3979-z.PubMedCrossRefGoogle Scholar
  86. 86.
    Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/19422077 PubMedCrossRefGoogle Scholar
  87. 87.
    Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–52. doi: 10.1056/NEJMra1403718.PubMedCrossRefGoogle Scholar
  88. 88.
    Lopez A, Collet-Fenetrier B, Belle A, Peyrin-Biroulet L. Patients’ knowledge and fear of colorectal cancer risk in inflammatory bowel disease. J Dig Dis. 2016;17:383–91. doi: 10.1111/1751-2980.12356.PubMedCrossRefGoogle Scholar
  89. 89.
    Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23. quiz 524 doi: 10.1038/ajg.2009.727.PubMedCrossRefGoogle Scholar
  90. 90.
    American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101–21.e1-13. doi: 10.1016/j.gie.2014.10.030.CrossRefGoogle Scholar
  91. 91.
    Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–89. doi: 10.1136/gut.2009.179804.PubMedCrossRefGoogle Scholar
  92. 92.
    Soetikno R, Subramanian V, Kaltenbach T, Rouse RV, Sanduleanu S, Suzuki N, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013;144:1349–52. 1352–6 doi: 10.1053/j.gastro.2013.04.008.PubMedCrossRefGoogle Scholar
  93. 93.
    Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, Fidder HH, Siersema PD, Dekker E, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015;110:1014–21. doi: 10.1038/ajg.2015.63.PubMedCrossRefGoogle Scholar
  94. 94.
    Bopanna S, Roy M, Das P, Dattagupta S, Sreenivas V, Mouli VP, et al. Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer. Intest Res. 2016;14:264–9. doi: 10.5217/ir.2016.14.3.264.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73. doi: 10.1002/cncr.24760.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564–75. doi: 10.1001/jama.2016.5989.CrossRefGoogle Scholar
  97. 97.
    Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216–24. doi: 10.1016/j.mayocp.2013.09.006.PubMedCrossRefGoogle Scholar
  98. 98.
    Williams R, White P, Nieto J, Vieira D, Francois F, Hamilton F. Colorectal cancer in African Americans: an update. Clin Transl Gastroenterol. 2016;7:e185. doi: 10.1038/ctg.2016.36.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739–50. doi: 10.1038/ajg.2009.104.PubMedCrossRefGoogle Scholar
  100. 100.
    O’Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187:343–8. doi: 10.1016/j.amjsurg.2003.12.020.PubMedCrossRefGoogle Scholar
  101. 101.
    Kim TJ, Kim ER, Hong SN, Chang DK, Kim Y-H. Long-term outcome and prognostic factors of sporadic colorectal cancer in young patients: a large institutional-based retrospective study. Medicine (Baltimore). 2016;95:e3641. doi: 10.1097/MD.0000000000003641.CrossRefGoogle Scholar
  102. 102.
    Scott RB, Rangel LE, Osler TM, Hyman NH. Rectal cancer in patients under the age of 50 years: the delayed diagnosis. Am J Surg. 2016;211:1014–8. doi: 10.1016/j.amjsurg.2015.08.031.PubMedCrossRefGoogle Scholar
  103. 103.
    Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8:288–98. doi: 10.1038/nrc2349.PubMedCrossRefGoogle Scholar
  104. 104.
    Stigliano V, Sanchez-Mete L, Martayan A, Anti M. Early-onset colorectal cancer: a sporadic or inherited disease? World J Gastroenterol. 2014;20:12420–30. doi: 10.3748/wjg.v20.i35.12420.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    de la Chapelle A. Microsatellite instability. N Engl J Med. 2003;349:209–10. doi: 10.1056/NEJMp038099.PubMedCrossRefGoogle Scholar
  106. 106.
    Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 2013;3:114. doi: 10.3389/fonc.2013.00114.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012;5:19–27. Available: http://www.ncbi.nlm.nih.gov/pubmed/22574233 PubMedPubMedCentralGoogle Scholar
  108. 108.
    Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059–72. doi: 10.1053/j.gastro.2009.12.065.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Sameer AS, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev. 2014;23:246–57. doi: 10.1097/CEJ.0000000000000019.PubMedCrossRefGoogle Scholar
  110. 110.
    Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011:792362. doi: 10.1155/2011/792362.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012;25:1128–39. doi: 10.1038/modpathol.2012.61.PubMedCrossRefGoogle Scholar
  112. 112.
    Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10. doi: 10.1016/j.humpath.2010.06.002.PubMedCrossRefGoogle Scholar
  113. 113.
    Raut CP, Pawlik TM, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res. 2004;568:275–82. doi: 10.1016/j.mrfmmm.2004.05.025.PubMedCrossRefGoogle Scholar
  114. 114.
    Cunningham D, Atkin W, Lenz H-J, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet (London, England). 2010;375:1030–47. doi: 10.1016/S0140-6736(10)60353-4.CrossRefGoogle Scholar
  115. 115.
    Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. 23:11–27. Available: http://www.ncbi.nlm.nih.gov/pubmed/15000146
  116. 116.
    Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/8484121 PubMedCrossRefGoogle Scholar
  117. 117.
    Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat. 2009;30:197–203. doi: 10.1002/humu.20942.PubMedCrossRefGoogle Scholar
  118. 118.
    Kempers MJE, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12:49–55. doi: 10.1016/S1470-2045(10)70265-5.PubMedCrossRefGoogle Scholar
  119. 119.
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57. Available: http://www.ncbi.nlm.nih.gov/pubmed/9823339 PubMedGoogle Scholar
  120. 120.
    Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77. doi: 10.1056/NEJM200001133420201.PubMedCrossRefGoogle Scholar
  121. 121.
    Losi L, Di Gregorio C, Pedroni M, Ponti G, Roncucci L, Scarselli A, et al. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol. 2005;100:2280–7. doi: 10.1111/j.1572-0241.2005.00223.x.PubMedCrossRefGoogle Scholar
  122. 122.
    Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000;342:137–8. doi: 10.1056/NEJM200001133420216.PubMedCrossRefGoogle Scholar
  123. 123.
    Durno C, Aronson M, Bapat B, Cohen Z, Gallinger S. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut. 2005;54:1146–50. doi: 10.1136/gut.2005.066092.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med. 1995;1:348–52. Available: http://www.ncbi.nlm.nih.gov/pubmed/7585065 PubMedCrossRefGoogle Scholar
  125. 125.
    Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg. 1998;227:51–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/9445110 PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Pucciarelli S, Agostini M, Viel A, Bertorelle R, Russo V, Toppan P, et al. Early-age-at-onset colorectal cancer and microsatellite instability as markers of hereditary nonpolyposis colorectal cancer. Dis Colon rectum. 2003;46:305–12. doi: 10.1097/01.DCR.0000054881.56204.F3.PubMedCrossRefGoogle Scholar
  127. 127.
    Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003;90:205–14. doi: 10.1002/bjs.4015.PubMedCrossRefGoogle Scholar
  128. 128.
    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18. doi: 10.1200/JCO.2005.01.086.PubMedCrossRefGoogle Scholar
  129. 129.
    Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74. doi: 10.1200/JCO.2009.23.3452.PubMedCrossRefGoogle Scholar
  130. 130.
    Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O’Connell MJ, et al. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol. 2012;30:2334–9. doi: 10.1200/JCO.2011.41.1975.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Perea J, Rueda D, Canal A, Rodríguez Y, Álvaro E, Osorio I, et al. Age at onset should be a major criterion for subclassification of colorectal cancer. J Mol Diagn. 2014;16:116–26. doi: 10.1016/j.jmoldx.2013.07.010.PubMedCrossRefGoogle Scholar
  132. 132.
    Silla IO, Rueda D, Rodríguez Y, García JL, de la Cruz VF, Perea J. Early-onset colorectal cancer: a separate subset of colorectal cancer. World J Gastroenterol. 2014;20:17288–96. doi: 10.3748/wjg.v20.i46.17288.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol from bed to bench. 2013;6:120–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/24834258 Google Scholar
  134. 134.
    Hawkins NJ, Tomlinson I, Meagher A, Ward RL. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer. 2001;84:232–6. doi: 10.1054/bjoc.2000.1554.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Chan TL, Curtis LC, Leung SY, Farrington SM, Ho JW, Chan AS, et al. Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes. Oncogene. 2001;20:4871–6. doi: 10.1038/sj.onc.1204653.PubMedCrossRefGoogle Scholar
  136. 136.
    Banerjea A, Hands RE, Powar MP, Bustin SA, Dorudi S. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Color Dis. 2009;11:601–8. doi: 10.1111/j.1463-1318.2008.01639.x.CrossRefGoogle Scholar
  137. 137.
    Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734–8. doi: 10.1093/jnci/djn359.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Cai G, Xu Y, Lu H, Shi Y, Lian P, Peng J, et al. Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers. Int J Color Dis. 2008;23:365–73. doi: 10.1007/s00384-007-0423-7.CrossRefGoogle Scholar
  139. 139.
    Silver A, Sengupta N, Propper D, Wilson P, Hagemann T, Patel A, et al. A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int J Cancer. 2012;130:1082–92. doi: 10.1002/ijc.26104.PubMedCrossRefGoogle Scholar
  140. 140.
    Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One. 2012;7:e45357. doi: 10.1371/journal.pone.0045357.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer. 2010;9:125. doi: 10.1186/1476-4598-9-125.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12:1059–68. doi: 10.1016/j.cgh.2013.08.015.PubMedCrossRefGoogle Scholar
  143. 143.
    Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 1993;2:425–34. doi: 10.1002/humu.1380020602.PubMedCrossRefGoogle Scholar
  144. 144.
    Nieuwenhuis MH, Vasen HFA. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007;61:153–61. doi: 10.1016/j.critrevonc.2006.07.004.PubMedCrossRefGoogle Scholar
  145. 145.
    Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology. 2009;137:1883–6. doi: 10.1053/j.gastro.2009.10.017.PubMedCrossRefGoogle Scholar
  146. 146.
    Campos FG, Figueiredo MN, Martinez CAR. Colorectal cancer risk in hamartomatous polyposis syndromes. World J Gastrointest Surg. 2015;7:25–32. doi: 10.4240/wjgs.v7.i3.25.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Chen H-M, Fang J-Y. Genetics of the hamartomatous polyposis syndromes: a molecular review. Int J Color Dis. 2009;24:865–74. doi: 10.1007/s00384-009-0714-2.CrossRefGoogle Scholar
  148. 148.
    Schreibman IR, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol. 2005;100:476–90. doi: 10.1111/j.1572-0241.2005.40237.x.PubMedCrossRefGoogle Scholar
  149. 149.
    Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35–45. doi: 10.1038/nrc2037.PubMedCrossRefGoogle Scholar
  150. 150.
    LaQuaglia MP, Heller G, Filippa DA, Karasakalides A, Vlamis V, Wollner N, et al. Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg. 1992;27:1085–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/1403541 PubMedCrossRefGoogle Scholar
  151. 151.
    Chiang J-M, Chen M-C, Changchien CR, Chen J-S, Tang R, Wang J-Y, et al. Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. Dis Colon rectum. 2003;46:904–10. doi: 10.1097/01.DCR.0000075210.01797.11.PubMedCrossRefGoogle Scholar
  152. 152.
    Tricoli JV, Seibel NL, Blair DG, Albritton K, Hayes-Lattin B. Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J Natl Cancer Inst. 2011;103:628–35. doi: 10.1093/jnci/djr094.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, et al. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol. 2007;25:5808–14. doi: 10.1200/JCO.2007.12.6102.PubMedCrossRefGoogle Scholar
  154. 154.
    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26. doi: 10.1200/JCO.2009.27.1825.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    National Comprehensive Cancer Network. NCCN guidelines—colon cancer [Internet]. Available: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
  156. 156.
    • Ben-Aharon R, Pelossof R, Elkabets M. Early-onset colorectal cancer—does the difference lie in epigenetics? Eur Cancer Congr. 2015:Abstract 2189. doi: 10.1016/S0959-8049(16)31108-X. This exploratory study investigated differences between somatic gene expression in cohorts of patients younger and older than age 50 years
  157. 157.
    Kirzin S, Marisa L, Guimbaud R, De Reynies A, Legrain M, Laurent-Puig P, et al. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PLoS One. 2014;9:e103159. doi: 10.1371/journal.pone.0103159.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat database: incidence—SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013)<Katrina/Rita Population Adjustment>−Linked To County Attributes - Total U.S., 1969–2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Louise C. Connell
    • 1
  • José Mauricio Mota
    • 1
  • Maria Ignez Braghiroli
    • 1
    • 2
    Email author
  • Paulo M. Hoff
    • 1
    • 2
  1. 1.Centro de OncologiaHospital Sírio-LibanêsSão PauloBrazil
  2. 2.Department of Radiology and Medical Oncology, Instituto do Câncer do Estado de São PauloFaculdade de Medicina da Universidade de São PauloSao PauloBrazil

Personalised recommendations